User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Estimating survival gain for economic evaluations with survival time as principal endpoint: A cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer

Primary tabs

Neymark, N. Adriaenssen, I Gorlia, Thierry [UCL] Caleo, S Bolla, M.

The problem of estimating expected outcomes for the economic evaluation of treatments for which the outcome of principal interest is (quality adjusted) survival time has so far not received sufficient attention in the literature. The best estimate of expected survival is mean survival time, but with censored survival data, the true survival time for all the subjects is not known, so the mean is not defined. A possible solution to this estimation problem is illustrated by a retrospective cost-effectiveness analysis of the addition of hormonal therapy to standard radiotherapy for patients with locally advanced prostate cancer, A recently proposed method is used to approach the problem caused by censored cost data, and the impact of uncertainty is assessed by bootstrap resampling techniques. Mean survival time is estimated by a restricted means analysis with the time point of restriction determined by statistical criteria. When average total costs and mean survival time is evaluated at this time point of restriction, the result is that the combined therapy (radiotherapy plus hormonal therapy) increases mean survival time by about 1 year, while reducing the costs per patient for the French health insurance system by 12 700 FF. The time point of restriction may also be determined by other criteria and mean survival time may be estimated by extrapolating the survival curves by means of various parametric survival distributions. We show that the exact results of the economic evaluation are decisively determined by the restriction time point chosen and the approach taken to estimate mean survival time. Copyright (C) 2002 John Wiley Sons, Ltd.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès restreint
Publication date 2002
Language Anglais
Journal information "Health Economics" - Vol. 11, no. 3, p. 233-248 (2002)
Peer reviewed yes
Publisher John Wiley & Sons Ltd (W Sussex)
issn 1057-9230
e-issn 1099-1050
Publication status Publié
Affiliation UCL
Keywords cost-effectiveness analysis ; locally advanced prostate cancer ; survival data ; censoring ; estimation of mean survival time
Links
  1. Neymark Niels, Assessing the Economic Value of Anticancer Therapies, ISBN:9783642721250, 10.1007/978-3-642-72123-6
  2. Iveson T.J., Hickish T., Schmitt C., Van Cutsem E., Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU, 10.1016/s0959-8049(99)00186-0
  3. McGuire W, Neugut A I, Arikian S, Doyle J, Dezii C M, Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer., 10.1200/jco.1997.15.2.640
  4. Thompson S. G, How should cost data in pragmatic randomised trials be analysed?, 10.1136/bmj.320.7243.1197
  5. Briggs Andrew, Gray Alastair, The Distribution of Health Care Costs and Their Statistical Analysis for Economic Evaluation, 10.1177/135581969800300410
  6. Hougaard Philip, Analysis of Multivariate Survival Data, ISBN:9781461270874, 10.1007/978-1-4612-1304-8
  7. Moeschberger M. L., Klein John P., A Comparison of Several Methods of Estimating the Survival Function When There is Extreme Right Censoring, 10.2307/2530660
  8. Pepe Margaret Sullivan, Fleming Thomas R., Weighted Kaplan-Meier Statistics: A Class of Distance Tests for Censored Survival Data, 10.2307/2531492
  9. Wright Janice C., Weinstein Milton C., Gains in Life Expectancy from Medical Interventions — Standardizing Data on Outcomes, 10.1056/nejm199808063390606
  10. Collett D., Modelling Survival Data in Medical Research, ISBN:9780412448904, 10.1007/978-1-4899-3115-3
  11. Survival Analysis. Techniques for Censored and Truncated Data. Springer: New York, 1997.
  12. Irwin J. O., The standard error of an estimate of expectation of life, with special reference to expectation of tumourless life in experiments with mice, 10.1017/s0022172400014443
  13. Karrison Theodore G., Use of Irwin's restricted mean as an index for comparing survival in different treatment groups—Interpretation and power considerations, 10.1016/s0197-2456(96)00089-x
  14. Pisters, Semin Oncol, 26, 202 (1999)
  15. Horwitz Eric M., Hanlon Alexandra L., Hanks Gerald E., Update on the treatment of prostate cancer with external beam irradiation, 10.1002/(sici)1097-0045(19981101)37:3<195::aid-pros10>3.0.co;2-c
  16. Bolla Michel, Gonzalez Dionisio, Warde Padraig, Dubois Jean Bernard, Mirimanoff René-Olivier, Storme Guy, Bernier Jacques, Kuten Abraham, Sternberg Cora, Gil Thierry, Collette Laurence, Pierart Marianne, Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin, 10.1056/nejm199707313370502
  17. Guide Pratique des Médicament. Maloine: Paris, 1996.
  18. Nomenclature Générale des Actes Professionel. Union des Caisses Nationales de Sécurités Sociales: Paris, 1994.
  19. Dictionnaire VIDA. Editions du Vidal: Paris, 1998.
  20. World Bank. World Health Development Report. Washington, DC, 1993.
  21. Cost-Effectiveness in Health and Medicin. Oxford University Press: New York, 1996.
  22. Peto R, Pike M C, Armitage P, Breslow N E, Cox D R, Howard S V, Mantel N, McPherson K, Peto J, Smith P G, Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples, 10.1038/bjc.1977.1
  23. Mark Daniel B., Hlatky Mark A., Califf Robert M., Naylor C. David, Lee Kerry L., Armstrong Paul W., Barbash Gabriel, White Harvey, Simoons Maarten L., Nelson Charlotte L., Clapp-Channing Nancy, Knight J. David, Harrell Frank E., Simes John, Topol Eric J., Cost Effectiveness of Thrombolytic Therapy with Tissue Plasminogen Activator as Compared with Streptokinase for Acute Myocardial Infarction, 10.1056/nejm199505253322106
  24. Messori A., Survival curve fitting using the Gompertz function: a methodology for conducting cost-effectiveness analyses on mortality data, 10.1016/s0169-2607(96)01788-9
  25. Messori A., Becagli P., Trippoli S., Tendi E., A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma, 10.1016/s0959-8049(96)00413-3
  26. Garg Mohan L., Rao B. Raja, Redmond Carol K., Maximum-Likelihood Estimation of the Parameters of the Gompertz Survival Function, 10.2307/2346545
  27. Cantor Alan B., Shuster Jonathan J., Parametric versus non-parametric methods for estimating cure rates based on censored survival data, 10.1002/sim.4780110710
  28. Lin D. Y., Feuer E. J., Etzioni R., Wax Y., Estimating Medical Costs from Incomplete Follow-Up Data, 10.2307/2533947
  29. Briggs Andrew H., Mooney Christopher Z., Wonderling David E., Constructing confidence intervals for cost-effectiveness ratios: an evaluation of parametric and non-parametric techniques using Monte Carlo simulation, 10.1002/(sici)1097-0258(19991215)18:23<3245::aid-sim314>3.0.co;2-2
  30. Heitjan Daniel F., Moskowitz Alan J., Whang William, Bayesian estimation of cost-effectiveness ratios from clinical trials, 10.1002/(sici)1099-1050(199905)8:3<191::aid-hec409>3.0.co;2-r
  31. Briggs Andrew, Fenn Paul, Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane, 10.1002/(sici)1099-1050(199812)7:8<723::aid-hec392>3.0.co;2-o
  32. Briggs Andrew H., A Bayesian approach to stochastic cost-effectiveness analysis, 10.1002/(sici)1099-1050(199905)8:3<257::aid-hec427>3.0.co;2-e
  33. O'Brien Bernie, Gafni Amiram, When Do the "Dollars" Make Sense? : Toward a Conceptual Framework for Contingent Valuation Studies in Health Care, 10.1177/0272989x9601600314
  34. Bolla M., Collette L., Gonzalez D., Warde P., Dubois J.B., Mirimanoff R., Storme G., Bernier J., Kuten A., Piérart M., Long term results of immediate adjuvant hormonal therapy with goserelin in patients with locally advanced prostate cancer treated with radiotherapy — A phase III EORTC study, 10.1016/s0959-8049(99)80699-6
  35. Glasziou Paul P., Cole Bernard F., Gelber Richard D., Hilden Jorgen, Simes R. John, Quality adjusted survival analysis with repeated quality of life measures, 10.1002/(sici)1097-0258(19980615)17:11<1215::aid-sim844>3.0.co;2-y
  36. Glick, Med Decision Making, 18, 63 (1998)
  37. Carides G. W., A regression-based method for estimating mean treatment cost in the presence of right-censoring, 10.1093/biostatistics/1.3.299
  38. Glick Henry A., Polsky Daniel, Willke Richard J., Schulman Kevin A., A Comparison of Preference Assessment Instruments Used in a Clinical Trial : Responses to the Visual Analog Scale from the EuroQol EQ-5D and the Health Utilities Index, 10.1177/0272989x9901900305
Bibliographic reference Neymark, N. ; Adriaenssen, I ; Gorlia, Thierry ; Caleo, S ; Bolla, M.. Estimating survival gain for economic evaluations with survival time as principal endpoint: A cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer. In: Health Economics, Vol. 11, no. 3, p. 233-248 (2002)
Permanent URL http://hdl.handle.net/2078.1/42281